Akebia Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -121.60%. Akebia Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 13.50.
Akebia Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -9.01%.
Akebia Therapeutics ROE % Adjusted to Book Value Related Terms
Akebia Therapeutics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Akebia Therapeutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics ROE % Adjusted to Book Value Chart
STU:AX9 vs TKNO, ORGO, SIGA: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -9.01% mean?
Akebia Therapeutics (STU:AX9) has a ROE % Adjusted to Book Value of -9.01% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' ROE % Adjusted to Book Value too high?
Akebia Therapeutics' current ROE % Adjusted to Book Value is -9.01%. Overall, Akebia Therapeutics has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' ROE % Adjusted to Book Value compare to TKNO and ORGO?
Akebia Therapeutics' ROE % Adjusted to Book Value of -9.01% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current ROE % Adjusted to Book Value is -9.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (STU:AX9) is currently considered Modestly Undervalued. The stock's GF Value™ is €1.12, compared to a current price of €0.98 — trading 12.6% below its estimated fair value. The current ROE % Adjusted to Book Value is -9.01%. Akebia Therapeutics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Akebia Therapeutics (STU:AX9), the current ROE % Adjusted to Book Value is -9.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?
Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be undervalued.
The current stock price of €0.98 is trading 12.6% below its estimated GF Value™ of €1.12.
GuruFocus considers Akebia Therapeutics to be Modestly Undervalued.
Key valuation signals for STU:AX9:
ROE % Adjusted to Book Value: -9.01%
GF Value™: €1.12 vs. price of €0.98 (12.6% below fair value)
No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
51GF Score
Get the complete analysis for STU:AX9
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AX9 has been successfully added to your 
